Arovella Therapeutics

CLDN18.2-CAR-iNKT cells robustly eliminated CLDN18.2-positive pancreatic and gastric cancer cells in serial tumour challenge assays. Armoured CAR-iNKT cells (with IL-12-TM) maintained killing of more than 97% of pancreatic and 82% of gastric tumour cells across four successive tumour challenges, outperforming non-armoured cells which lost control after two challenges. IL-12-TM armouring also enhanced CAR-iNKT cell expansion, demonstrating improved durability and potency.

CLDN18.2-CAR-iNKT cells robustly eliminated CLDN18.2-positive pancreatic and gastric cancer cells in vitro across serial tumour challenge assays. Armoured CAR-iNKT cells (with IL-12-TM) maintained killing of more than 97% of pancreatic and 82% of gastric tumour cells after four successive tumour challenges, outperforming non-armoured cells which lost control after two challenges. IL-12-TM armouring also significantly enhanced CAR-iNKT cell expansion.

CLDN18.2 CAR-iNKT cells robustly eliminated CLDN18.2-positive pancreatic and gastric cancer cells in an in vitro serial tumour challenge assay. Armoured CAR-iNKT cells (with IL-12-TM) maintained killing of more than 97% of pancreatic and 82% of gastric tumour cells after four successive tumour challenges, outperforming non-armoured cells which lost control after two challenges. IL-12-TM armouring also enhanced CAR-iNKT cell expansion, demonstrating improved durability and potency.